ERBB2 and breast cancer: Twenty-two patients diagnosed with BC participated in a longitudinal study to evaluate the effects of CTx on the vasculature with measurements before, during, and approximately 1 month after the final dose of Dox or anti-HER2 therapy received during standard-of-care treatment.